Compare AGYS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGYS | BEAM |
|---|---|---|
| Founded | 1963 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1994 | 2019 |
| Metric | AGYS | BEAM |
|---|---|---|
| Price | $106.83 | $27.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $111.67 | $50.75 |
| AVG Volume (30 Days) | 356.4K | ★ 2.7M |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 67.07 | ★ 82.31 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $319,312,000.00 | $24,000.00 |
| Revenue This Year | $17.65 | N/A |
| Revenue Next Year | $14.36 | $33.77 |
| P/E Ratio | $80.64 | ★ N/A |
| Revenue Growth | 15.85 | ★ 33.33 |
| 52 Week Low | $61.50 | $15.60 |
| 52 Week High | $144.82 | $38.26 |
| Indicator | AGYS | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 34.36 |
| Support Level | $103.30 | $26.96 |
| Resistance Level | $114.25 | $29.68 |
| Average True Range (ATR) | 4.41 | 2.45 |
| MACD | -0.71 | -0.95 |
| Stochastic Oscillator | 44.96 | 5.82 |
Agilysys Inc is engaged in hospitality software, delivering cloud-native SaaS and on-premise solutions for hotels, multi-amenity resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It operates across the Americas, Europe, the Middle East, Africa, Asia-Pacific, and India with headquarters located in Alpharetta, GA. The Company has one reportable segment serving the global hospitality industry.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.